{"id":"W3168407158","doi":"10.1200/jco.2021.39.15_suppl.8006","title":"Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; Institute of Cancer Research; McGill University Health Centre; University of Calgary","funders":"Pfizer","keywords":"Medicine; Cytokine release syndrome; Common Terminology Criteria for Adverse Events; Adverse effect; Neutropenia; Internal medicine; Multiple myeloma; Gastroenterology; Anemia; Toxicity; Chimeric antigen receptor; Oncology; Immunology; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002502042,0.0001860695,0.001654747,0.0002839169,0.00004444523,0.00001411496,0.0001657843,0.0004751503,0.0008905152],"category_scores_gemma":[0.004048767,0.0001243208,0.0002253539,0.000467216,0.0003151753,0.0001753652,0.00008640144,0.00150611,0.000008018424],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001988142,"about_ca_system_score_gemma":0.002054196,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001931834,"about_ca_topic_score_gemma":0.0001377227,"domain_scores_codex":[0.9952179,0.000872274,0.002521382,0.0003320866,0.0007424827,0.0003138262],"domain_scores_gemma":[0.9928342,0.003978402,0.001434086,0.0003641419,0.001050237,0.000338995],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1919603,0.008018151,0.6085715,0.0001477701,0.0003834761,0.001782247,0.0003223863,0.00001379111,0.02283327,0.000009073268,0.0007607621,0.1651973],"study_design_scores_gemma":[0.05807777,0.01620515,0.8884302,0.0003134708,0.000102512,0.0001283815,0.0001816493,0.00007814161,0.001418151,0.00001133244,0.03493164,0.0001215534],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9959598,0.0005506964,0.00006341592,0.00133633,0.0004335226,0.0004948425,0.00001006487,0.00000702436,0.00114432],"genre_scores_gemma":[0.9921785,0.003297985,0.003027695,0.0002947998,0.0003466572,0.000001730922,0.00003644734,0.00003419215,0.00078198],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2798588,"threshold_uncertainty_score":0.9750517,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06914840343259031,"score_gpt":0.4273267521688274,"score_spread":0.3581783487362371,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}